Clinical trialNCT06994845RecruitingPhase 3Interventional

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

SponsorNovartis PharmaceuticalsEnrollment31Primary Immunoglobulin A Nephropathy (IgAN)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (including CV surveillance) of iptacopan in primary immunoglobulin A nephropathy (IgAN) pediatric patients aged 2 to \<18 years.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Novartis Investigative Site
Brisbane, Queensland, Australia
Recruiting
Novartis Investigative Site
Nedlands, Western Australia, Australia
Recruiting

China

Novartis Investigative Site
Hangzhou, Zhejiang, China
Recruiting
Novartis Investigative Site
Beijing, China
Recruiting

Hong Kong

Novartis Investigative Site
Hong Kong, Hong Kong
Recruiting

Israel

Novartis Investigative Site
Beersheba, Israel
Recruiting
Novartis Investigative Site
Haifa, Israel
Recruiting
Novartis Investigative Site
Jerusalem, Israel
Recruiting
Novartis Investigative Site
Petah Tikva, Israel
Recruiting

Japan

Novartis Investigative Site
Toyoake, Aichi-ken, Japan
Recruiting
Novartis Investigative Site
Kurume, Fukuoka, Japan
Recruiting
Novartis Investigative Site
Ohtsu, Shiga, Japan
Recruiting
Novartis Investigative Site
Fuchū, Tokyo, Japan
Recruiting

Saudi Arabia

Novartis Investigative Site
Riyadh, Saudi Arabia
Recruiting

United States

Childrens Hospital Colorado
Aurora, Colorado, United States
Bradley Dixon
Recruiting
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Rebecca Scobell
Recruiting
Prim Childrens Hosp Inv Pharm
Salt Lake City, Utah, United States
Raoul Nelson
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Iptacopan →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 Nov 2025
Primary completion: 28 Jun 2030
Completion: 30 Jun 2030
Last update posted: 1 Jun 2026
Registered enrollment: 31
Registry id: NCT06994845

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.